Skip to content
Search

Latest Stories

Health secretary accuses NHS gender care influenced by 'cultural values'

Health secretary accuses NHS gender care influenced by 'cultural values'

Wes Streeting challenges plans for improving mental health assessments amidst growing scrutiny over NHS gender care 

In a recent parliamentary discussion concerning NHS gender care in light of the Cass review, Health Secretary Victoria Atkins claimed that a significant surge in gender referrals was "driven by myth," contrary to evidence prioritizing "safety and biological reality."


Atkins highlighted that the NHS's primary gender identity development service, located at the Tavistock and Portman NHS Foundation Trust, had received fewer than 60 referrals for children and young people in 2009.

However, there was a substantial increase in referrals for puberty blockers and cross-sex hormone therapy, with a 34 percent rise noted.

By 2016, the number of referrals skyrocketed to over 1,700 annually, with more than half of them being teenage girls.

This figure surged to over 5,000 children and young people by 2022.

Attributing the "exponential rise" to "myth" and "fashionable cultural values," Atkins criticized the shift away from evidence-based practices, emphasizing the importance of considering safety and biological reality.

She also raised concerns about the lack of thoughtful consideration for the broader needs of teenagers, particularly girls, who comprised three-quarters of the referrals and criticized the tendency for near-uniform prescriptions to address various issues, including neurodivergent conditions and childhood traumas, without adequate assessment.

These remarks follow with the release of the final report of the Cass review, which includes 27 recommendations for improving access and standardizing care for gender dysphoria.

The report proposes the establishment of regional multidisciplinary centers to facilitate smoother transitions between adolescent and adult services.

During the discussion, Labour's shadow secretary of state for health and social care, Wes Streeting, challenged the health secretary on plans to reduce waiting times for assessments of mental health and neurodevelopmental conditions.

Streeting characterized the findings of the Cass review as scandalous.

"It is a scandal that children and young people are waiting far too long—often years—for care while their wellbeing deteriorates and their childhood slips away."

Furthermore, Atkins warned private providers about the highly regulated nature of prescribing, noting that the Care Quality Commission (CQC) had not licensed any gender clinic to prescribe hormone blockers or cross-sex hormones to those under 16.

She cautioned that clinics engaging in such practices could face serious regulatory consequences, including license revocation and clinician disbarment.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less